News

Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.
Zacks Investment Research on MSN4d
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...
BioWorld6d
Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B
Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...
Regeneron Pharmaceuticals (NasdaqGS:REGN) Secures US$80 Million Deal For GLP-1/GIP Drug Rights
Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094.
Pharmaceutical Technology on MSN6d
Regeneron to acquire rights for Hansoh’s HS-20094 therapy
Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...